Drug Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

Market demand for cytotoxic drugs is leading CMOs to expand their API manufacturing and formulation services.

Investing in High-Potency Manufacturing

Natural gums and mucilage have been widely explored as pharmaceutical excipients. The goal of this study was to extract mucilage from the leaves of Aloe barbadensis Miller and to study its functionality as an excipient in pharmaceutical sustained-release tablet formulations.

Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets

The EIP process addresses the problems encountered with numerous questionnaires when qualifying excipient manufacturers.

The Excipient Information Package, A Win-Win Solution

The crystalline structure of pharmaceutical solids can sometimes be altered during processing. X-ray powder diffraction and near infrared spectroscopy can be used to determine the amorphous and crystalline content of a model substance. The two techniques' precision, accuracy, detection limit and the speed of analysis are compared.

Monitoring processing-induced crystallinity changes

Company Notes: Gibraltar expands facilities; Allozyne appoints new president and CEO, more.

Company Notes: Gibraltar Expands Facilities; Allozyne Appoints New President and CEO, More

Angie Drakulich was editorial director of Pharmaceutical Technology.

After a whirlwind of negative press this fall regarding the safety of cough and cold medications for children under age 6, the US Food and Drug Administration?s Nonprescription Drugs and Pediatric Advisory Committees have recommended such over-the-counter drugs no longer be used for young children.

FDA Committees Recommend Ban on Cough and Cold Medications for Young Children

Company and People Notes: ImClone, BMS, and Merck form agreement; CRI Worldwide names new CEO, more.

Company and People Notes: ImClone, BMS, and Merck Form Agreement; CRI Worldwide Names New CEO; More

Company and People Notes: Orexo acquires Biolipox, Avalon cofounder resigns, more...

Company and People Notes: Orexo Acquires Biolipox, Avalon Cofounder Resigns, More

GlaxoSmithKline and Synta Pharmaceuticals agreed to jointly develop and commercialize STA-4783. The drug is an injectable, small-molecule, oxidative stress inducer for treating metastatic melanoma that is entering Phase III clinical development.

GSK, Synta Pharmaceuticals Form $1-Billion Drug-Development Pact

CPhI Worldwide, the large trade show of suppliers of active pharmaceutical ingredients (APIs), intermediates, and excipients, took on a decidedly international presence.

Ingredients